01 1Promacta
02 8Promacta/Revolade
03 5Revolade/Promacta
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 1,738
2019 Revenue in Millions : 1,416
Growth (%) : 23
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 1,738
2019 Revenue in Millions : 1,416
Growth (%) : 23
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 2,016
2020 Revenue in Millions : 1,738
Growth (%) : 16
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 2,016
2020 Revenue in Millions : 1,738
Growth (%) : 16
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 2,088
2021 Revenue in Millions : 2,016
Growth (%) : 4
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 2,088
2021 Revenue in Millions : 2,016
Growth (%) : 4
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 2,269
2022 Revenue in Millions : 2,088
Growth (%) : 9
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 2,269
2022 Revenue in Millions : 2,088
Growth (%) : 9
EltroMbopag diethanolaMine salt
Main Therapeutic Indication : Oncology
Currency : USD
2014 Revenue in Millions : 24.20%
2013 Revenue in Millions :
Growth (%) :
EltroMbopag diethanolaMine salt
Main Therapeutic Indication : Oncology
Currency : USD
2015 Revenue in Millions : 0
2014 Revenue in Millions : 402
Growth (%) : New Launch
LOOKING FOR A SUPPLIER?